SAVER
Research type
Research Study
Full title
Supporting Adherence - Value-based Economic Resource
IRAS ID
325251
Contact name
Prakash Punjabi
Contact email
Sponsor organisation
Inavya Ventures Ltd
Duration of Study in the UK
1 years, 6 months, 15 days
Research summary
Cardiovascular disease is one of the biggest health challenges in the National Health Service; although it impacts everyone with that condition, people with Black or South Asian background seem to be mostly affected primarily due to the high prevalence of diabetes; this gets further compounded by various language barriers to access healthcare. Imperial College Healthcare NHS Trust is in West London and has a mixture of white and various ethnic minority patients.
It is vital that post-operative patients follow their treatment plan including medication, nutrition, fluid intake and mobility plan. Project SAVER is an 18-month study with participation by Inavya, a clinical research team from Imperial College Healthcare NHS Trust, and Ipsos. The SAVER study will surface medication adherence - with associated costs and savings - to patients and clinicians. This actionable insight could enable clinicians to make better and faster decisions to optimally meet a patient's need; and it could enable patients to learn of the impacts associated with medication non-adherence: saving lives and money, and research how healthcare is delivered across the NHS and global markets.
Patients enrolled in the study will carry on with standard care treatment and in addition as part of the research study will be using a mobile application called Avatr. Patients will enter in the Avatr mobile application several non-identifiable responses (e.g. age, gender, ethnicity etc.) and answer generic questions which could potentially support patients with improvements in behavioural change, nutritional and exercise habits for example heart rate, weight, blood pressure and compare their responses to the national average using a colour-coded range of response for low (green), moderate (orange) and high (red) to identify risk factors. med non-adhere by prompts.
We will approach 25 patients on day 4 of the postoperative phase (patient still hospitalised) to consider participation in the study. We will discuss the study and the possibility of using ‘Avatr’ and on day 5 upon informed consent, the patient will be part of the study group. The clinical research team will show the patient a demo of how to interact and familiarise themselves with the app to answer any questions they may have before they get discharged which is the first out of the 90 days of the study.
The participants will interact with Avatr for approximately 90 days between the day of discharge and their telephone follow-up approximately 90 upon discharge. In those 90 days, the participants will interact with the Avatr app. The patients' demographics, medication history, and nutritional & mobility habits will be shared by the participant via the Avatr app in a pseudonymised format to avoid any breach of confidentiality.
Avatr will support the patients' post-discharge care plan by sending prompts and reminders to take their medication, improve their nutritional & fluid intake habits and mobilise throughout the day. During the 90-day period the participants will be asked to also answer the EQ-5D-5L and Resource use questionnaires on week 8 and 12 via the Avatr app. Ipsos will translate the data collected by producing a health economics analysis to better understand the potential economic impact on the NHS.
REC name
London - Camberwell St Giles Research Ethics Committee
REC reference
23/PR/0854
Date of REC Opinion
11 Sep 2023
REC opinion
Further Information Favourable Opinion